![](https://cdn.sanity.io/images/0vv8moc6/onclive/5d03a59e58db1ce67e485b7c1ef868268969fb4e-1200x1200.jpg?fit=crop&auto=format)
EMA Grants Orphan Medicinal Product Designation to Rivoceranib/Camrelizumab in First-Line Unresectable HCC
The European Medicines Agency (EMA) has granted orphan medicinal product designation to the combination of rivoceranib and camrelizumab as a potential first-line treatment for patients with unresectable hepatocellular carcinoma (HCC).1 “This significant …